Loading...
XKRX
001065
Market cap407mUSD
Dec 05, Last price  
29,500.00KRW
1D
8.26%
1Q
2.79%
Jan 2017
38.58%
Name

JW Pharmaceutical Corp

Chart & Performance

D1W1MN
XKRX:001065 chart
P/E
10.48
P/S
0.95
EPS
2,814.89
Div Yield, %
—
Shrs. gr., 5y
0.10%
Rev. gr., 5y
7.07%
Revenues
719.38b
-3.89%
385,010,282,000437,648,380,000455,146,860,000443,275,672,000431,007,281,000397,084,758,770394,182,301,740412,791,234,930434,352,380,160467,465,120,990502,918,586,610537,181,974,040511,335,342,730547,335,707,800606,584,944,780684,351,099,240748,526,707,810719,375,756,000
Net income
65.04b
+75.75%
8,761,048,0006,433,178,00010,918,718,0005,600,272,000-9,803,596,000-20,393,601,0002,274,880,2701,446,877,4801,961,427,000-10,933,544,000-742,474,3808,056,888,860-25,275,015,880-15,275,470,490-1,441,453,46031,891,678,69037,006,333,99065,040,121,000
CFO
79.39b
-8.91%
14,818,649,000-1,347,997,000-11,118,758,000-11,679,166,000-18,183,738,20064,214,781,68018,724,504,4407,279,097,730-4,174,929,9206,738,635,67033,450,172,29052,109,932,81055,531,084,79063,054,366,97018,123,982,17056,764,438,56087,157,236,38079,391,872,000
Dividend
Dec 27, 2023425 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
URL
https://www.jw-pharma.co.kr/
IPO date
Jun 14, 1976
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT